Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Sean P. Bohen, M.D., President and Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, California.

The presentation will be accessible via live webcast, along with any accompanying materials, through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be made available at the same location following the presentation.

News Market Reaction – OLMA

-4.46%

-4.46% Session move

In the trading session that priced this news, OLMA declined 4.46%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14, 2025 at 3:45 p.m. PT (6:45 p.m. ET).

A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

When is Olema Pharmaceuticals (OLMA) presenting at the 2025 J.P. Morgan Healthcare Conference?

Olema Pharmaceuticals (OLMA) will present on Tuesday, January 14, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

How can investors watch Olema's (OLMA) presentation at the J.P. Morgan Healthcare Conference?

Investors can watch the presentation via live webcast through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be available afterward.

Who will represent Olema Pharmaceuticals (OLMA) at the 2025 J.P. Morgan Healthcare Conference?

Sean P. Bohen, M.D., President and Chief Executive Officer of Olema Pharmaceuticals, will represent the company at the conference.

What is the main focus of Olema Pharmaceuticals' (OLMA) research and development?

Olema Pharmaceuticals focuses on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond.